2022 Chinese Expert Consensus on the Diagnosis and Treatment of Borderline Developmental Dysplasia of the Hip (2022 Edition)
This consensus, formulated by multiple Chinese orthopedic and sports medicine societies using the GRADE system and RIGHT reporting standards, provides 38 evidence - based recommendations covering the definition, diagnosis, non - surgical/surgical treatment, and follow - up of Borderline Developmental Dysplasia of the Hip (BDDH), aiming to standardize clinical practice. Below is the structured English summary.
Core Definition & Diagnostic Criteria
-
Definition
-
BDDH refers to a hip status between normal hips and overt adult DDH, defined by a lateral center - edge angle (LCEA) of 20° - 25° on weight - bearing anteroposterior pelvic radiographs (measured via Wiberg’s method).
-
Symptomatic BDDH is diagnosed when LCEA is 20° - 25° along with hip pain, limited mobility, and/or instability.
-
Key Diagnostic Workup
|
Component |
Recommendations |
Evidence Level |
|
Clinical Assessment |
Collect history of pain, mechanical symptoms, and instability; perform impingement/instability tests (e.g., flexion - abduction - external rotation, pivot shift) |
Strong, Moderate |
|
Imaging |
Weight - bearing AP pelvis X - ray for LCEA; MRI for labral/cartilage lesions and microinstability; CT for acetabular morphology (optional) |
Strong, Moderate |
|
Instability Evaluation |
Use the term “hip instability” (avoid “microinstability”); diagnose via clinical signs + imaging + dynamic tests |
Good Practice Statement |
Non - Surgical Management
-
Indications: Symptomatic BDDH without severe instability, no advanced joint degeneration, and no prior standardized conservative treatment.
-
Core Measures
-
Rehabilitation: Focus on hip abductor/core strengthening, gait training, and activity modification to enhance dynamic stability.
-
Pharmacotherapy: Short - term NSAIDs for pain relief; avoid long - term use to prevent adverse effects.
-
Injections: Intra - articular corticosteroids or hyaluronic acid for refractory pain (selective use); ultrasound - guided for safety.
-
Response Evaluation: Reassess after 3 - 6 months. If symptoms persist or instability worsens, consider surgical intervention.
Surgical Intervention
-
Indications
-
Persistent symptoms despite ≥6 months of conservative treatment.
-
Confirmed labral tears, chondral lesions, or hip instability affecting function.
-
Surgical Options & Recommendations
|
Procedure |
Indications |
Recommendations |
Evidence Level |
|
Hip Arthroscopy |
Labral tears, chondral injury, femoroacetabular impingement (FAI), mild - moderate instability |
Labral repair + rim trimming; address FAI (Cam/Pincer) simultaneously |
Strong, Low |
|
Periacetabular Osteotomy (PAO) |
Young patients with LCEA 20° - 22°, poor acetabular coverage, and no advanced OA |
Improve coverage while preserving joint function |
Conditional, Low |
|
Capsular Plication |
Isolated instability without severe acetabular dysplasia |
Reinforce capsule to enhance static stability |
Conditional, Very Low |
-
Postoperative Care: Early mobilization with protected weight - bearing; rehabilitation to restore strength and motion; avoid high - impact activities for 6 - 12 months.
Special Populations & Follow - up
-
Young Adults: Prioritize joint - preserving surgery (arthroscopy/PAO) to delay OA progression.
-
Elderly Patients: Non - surgical treatment first; arthroplasty for advanced OA.
-
Follow - up Protocol: Clinical assessment + X - ray at 3, 6, 12 months post - treatment; annual long - term follow - up to monitor LCEA, pain, and OA changes.
Core Treatment Principles
-
Individualize treatment based on symptoms, imaging, age, and activity level.
-
Non - surgical treatment is the first - line for symptomatic BDDH; surgery is reserved for refractory cases.
-
Joint - preserving surgery is preferred for young patients to maintain hip function.